echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Over 400 million euros, Orion and Alligator Bioscience develop dual-antibody therapy

    Over 400 million euros, Orion and Alligator Bioscience develop dual-antibody therapy

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 18, Alligator Bioscience announced that the company has signed a research cooperation and licensing agreement with Finland-based Orion Corporation (Orion) to jointly discover and develop new bispecific antibodies (bi-antibody) cancers Therapy


    This research collaboration will focus on the discovery of novel bispecific antibodies on the immuno-oncology targets selected by Orion


    Source: Alligator Bioscience official website

    Reference materials:

    [1] Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.